| Description | This product is a human neutralizing antibody binding EBOV GP (Ebola virus glycoprotein), named rEBOV-548. It bounds to a glycan cap epitope, possesses neutralizing and Fc-mediated effector function activity and it potently neutralizes EBOV and BDBV. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | EBOV |
| Cross Reactivity | BDBV, SUDV |
| Epitope | rEBOV-548 recognizes the glycan cap region and bounds nearly perpendicular to the surface of the GP. |
| Neutralization Mechanism | EBOV-548 binds to the glycan cap, removed this steric hindrance by dislodging and mimicking the β18-β18' hairpin obscuring the 310 pocket. |
| IC50 | EBOV: 1.601 μg/mL BDBV: 2.262 μg/mL SUDV: incomplete neutralization (< 12%) |
| EC50 | EBOV: 6 ng/mL BDBV: 7 ng/mL SUDV: 132 ng/mL The EC50 value was determined by ELISA assay. |
| Isotype | Human IgG1 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; BLI; FC; Neut |
| Application Notes | ELISA: This antibody was diluted in blocking buffer 1:5, added to the wells, and incubated for 1 h at ambient temperature. Bio-layer interferometry (BLI): Binding was performed using serial two-fold dilutions of mAbs. Neutralization assay (Neut): 200 μg/mL |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | EBOV GP |
| Alternative Name | Ebolavirus glycoprotein |
| Research Area | Infectious Disease |
| Related Disease | Severe hemorrhagic fever |
